141 related articles for article (PubMed ID: 36386119)
21. The histomorphologic spectrum of primary cutaneous diffuse large B-cell lymphoma: a study of 79 cases.
Plaza JA; Kacerovska D; Stockman DL; Buonaccorsi JN; Baillargeon P; Suster S; Kazakov DV
Am J Dermatopathol; 2011 Oct; 33(7):649-55; quiz 656-8. PubMed ID: 21937906
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement.
Lee S; Yamauchi T; Kinoshita K; Imamura S; Kamiya K
J Clin Exp Hematop; 2017 Oct; 57(2):64-68. PubMed ID: 28883219
[TBL] [Abstract][Full Text] [Related]
23. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
24. Dermoscopic follow-up of therapeutic response in mantle cell lymphoma with secondary involvement of the scalp.
Swoboda R; Kaminska-Winciorek G; Jaworska M; Giebel S
J Cosmet Dermatol; 2019 Oct; 18(5):1438-1440. PubMed ID: 30520227
[TBL] [Abstract][Full Text] [Related]
25. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
26. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
27. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C
J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522
[TBL] [Abstract][Full Text] [Related]
28. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
[TBL] [Abstract][Full Text] [Related]
29. Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features.
Muniesa C; Pujol RM; Estrach MT; Gallardo F; García-Muret MP; Climent J; Salar A; Servitje O
J Am Acad Dermatol; 2012 Apr; 66(4):650-4. PubMed ID: 21816504
[TBL] [Abstract][Full Text] [Related]
30. Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.
Lucioni M; Berti E; Arcaini L; Croci GA; Maffi A; Klersy C; Goteri G; Tomasini C; Quaglino P; Riboni R; Arra M; Dallera E; Grandi V; Alaibac M; Ramponi A; Rattotti S; Cabras MG; Franceschetti S; Fraternali-Orcioni G; Zerbinati N; Onida F; Ascani S; Fierro MT; Rupoli S; Gambacorta M; Zinzani PL; Pimpinelli N; Santucci M; Paulli M
Cancer Med; 2016 Oct; 5(10):2740-2755. PubMed ID: 27665744
[TBL] [Abstract][Full Text] [Related]
31. Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Gupta E; Accurso J; Sluzevich J; Menke DM; Tun HW
Rare Tumors; 2015 Dec; 7(4):6067. PubMed ID: 26788279
[TBL] [Abstract][Full Text] [Related]
32. Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea.
Kim MJ; Hong ME; Maeng CH; Jung HA; Hong JY; Choi MK; Kim SJ; Ko YH; Kim WS
Int J Hematol; 2015 Mar; 101(3):273-8. PubMed ID: 25552248
[TBL] [Abstract][Full Text] [Related]
33. F-18 FDG PET/CT in staging and response assessment of primary cutaneous diffuse large B-cell lymphoma (leg type).
Datta D; Pandey RR; Kumar R; Sharma R; Vedant D
Eur J Hybrid Imaging; 2023 Aug; 7(1):15. PubMed ID: 37605015
[TBL] [Abstract][Full Text] [Related]
34. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
35. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
Yang QX; Pei XJ; Tian XY; Li Y; Li Z
Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
[TBL] [Abstract][Full Text] [Related]
36. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
37. Diffuse Large B-cell Lymphoma (Leg Type) Originating in the Skin of the Right Cheek Region: A Case Report and Literature Review.
Wei Y; Liu L; Bu L; Zhan X; Xu H; Wang S
Ear Nose Throat J; 2023 Sep; ():1455613231202192. PubMed ID: 37776289
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.
Al Dhafiri M; Sicre de Fontbrune F; Marinho E; Deschamps L; Di-Lucca J; Crickx B; Descamps V
Clin Case Rep; 2019 May; 7(5):964-967. PubMed ID: 31110725
[TBL] [Abstract][Full Text] [Related]
39. Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges.
Wobser M; Kneitz H; Bröcker EB; Becker JC
J Dtsch Dermatol Ges; 2011 Mar; 9(3):204-11. PubMed ID: 21122066
[TBL] [Abstract][Full Text] [Related]
40. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
